Atricure, Inc. ((ATRC)) announced an update on their ongoing clinical study.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Study Overview: AtriCure, Inc. is conducting a multicenter patient registry titled ‘A Multicenter Patient Registry for Outcomes of Inappropriate Sinus Tachycardia and Postural Orthostatic Tachycardia Syndrome Treatment.’ The study aims to gather real-world safety and performance data on AtriCure devices used for ablating cardiac tissue in treating Inappropriate Sinus Tachycardia (IST) and Postural Tachycardia Syndrome (POTS). This research is significant as it seeks to enhance treatment outcomes for these conditions.
Intervention/Treatment: The study tests AtriCure’s commercially available devices, which are used in epicardial and endocardial hybrid ablation procedures. These devices aim to treat IST and POTS by targeting cardiac tissue.
Study Design: This observational study employs a cohort model to collect both retrospective and prospective data. It does not involve random allocation or masking, focusing instead on real-world application and outcomes.
Study Timeline: The study began on October 28, 2021, with an anticipated primary completion within 12 months. The latest update was submitted on October 16, 2025, indicating ongoing recruitment and data collection efforts.
Market Implications: The study’s progress could positively influence AtriCure’s stock performance by demonstrating the efficacy and safety of its devices, potentially boosting investor confidence. As the company competes in the cardiac ablation market, successful outcomes could enhance its competitive edge.
The study is currently ongoing, with further details available on the ClinicalTrials portal.